CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER
21-307

Pharmacology Review(s)
REVIEWS AND EVALUATION OF PHARMACOLOGY/TOXICOLOGY DATA

Key words:
Reviewer Name: Kumar D. Mainigi
Division Name: Dermatologic and Dental Drug Products, HFD-540
Review completion date:
Electronic file number:
NDA 21-307 (000)/09-29-2000
Information to sponsor: None
Sponsor: Schering-Plough Health Care Products
Three Oak Way
Berkley Heights, NJ 07922-0603
Manufacturer:

Drug: Butenafine Hydrochloride Cream 1% (Rx to OTC switch)
Code Name: KP-363
Chemical Name: N-4-tert-Butylbenzyl-N-methyl-1-naphthalenemethylamine Hydrochloride
Molecular Formula/Molecular Weight: C_{23}H_{27}N.HCl/353.93

\begin{center}
\includegraphics[width=0.5\textwidth]{butenafine_hcl_structure}
\end{center}

Butenafine HCl

Drug class: Antifungal
Indication: Treatment of athlete's foot, jock itch, and ringworm.
Relevant submissions
INDs:

NDAs:
20-524: Mentax^R (butenafine HCl) Cream 1% for the treatment of tinea pedis (approved 10/18/96)
20-663: Mentax^R (butenafine HCl) Cream 1% for the treatment of tinea corporis and tinea cruris (approved 12/31/96)
Route of administration: Topical

Clinical formulation: Butenafine HCl Cream 1% (PDC-010-C-003)

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Percentage (w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purified water USP</td>
<td></td>
</tr>
<tr>
<td>Propylene glycol dicaprylate</td>
<td></td>
</tr>
<tr>
<td>Glycerine USP</td>
<td></td>
</tr>
<tr>
<td>Cetyl alcohol NF</td>
<td></td>
</tr>
<tr>
<td>Glyceryl monostearate</td>
<td></td>
</tr>
<tr>
<td>White petrolatum USP</td>
<td></td>
</tr>
<tr>
<td>Stearic acid NF</td>
<td></td>
</tr>
<tr>
<td>Polyoxyethylene cetyl ether</td>
<td></td>
</tr>
<tr>
<td>Butenafine HCl</td>
<td>1.00</td>
</tr>
<tr>
<td>Benzyl alcohol NF</td>
<td></td>
</tr>
<tr>
<td>Diethanolamine NF</td>
<td></td>
</tr>
<tr>
<td>Sodium benzoate NF</td>
<td></td>
</tr>
</tbody>
</table>

Disclaimer: The information submitted by the sponsor is utilized to prepare this review.

Proposed clinical use: Butenafine HCl Cream 1% was approved as a prescription drug in 1996 for the treatment of tinea pedis (athlete's foot), tinea corporis (ring worm), and tinea cruris (jock itch). Now, the new sponsor plans to market the same formulation as an Over- the-Counter (OTC) drug product for the same indications. For this purpose, this sponsor has obtained written permission from Bertek Pharmaceuticals, Inc.

Previous human experience and drug history: Butenafine HCl cream 1% has been marketed as a prescription drug in USA (1996), Japan (1992), South Korea (1994), and Indonesia (1997). The same formulation is marketed in Canada as an OTC drug product under the trade names Dr. Scholl'sR Athlete's Foot Cream since April 1997. To date, no adverse effects of any clinical significance have been reported.

Non-clinical studies: Over the years, a number of applications have been submitted to support the different antifungal formulations of the active ingredient, butenafine hydrochloride. To support these drug applications, the sponsor has extensively evaluated the safety of this compound in a wide spectrum of in vivo and in vitro nonclinical and clinical studies. These studies were conducted with the tablet, cream, solution and gel formulations. The animal safety profile for butenafine hydrochloride has been well established, therefore, there are no non-clinical safety issues involved in Rx-to-OTC switch of this drug.
The OTC formulation will be identical to the approved prescription drug product.

Because of the well-established safety profile of butenafine hydrochloride, no new non-clinical studies were requested or required to support the safety of this already approved drug product.

**Overall summary of Pharmacology and Toxicology:** Since review of its first drug application (IND Butenafine HCl Cream 1%), butenafine HCl has been extensively evaluated in cream, optimized cream, gel, nail gel, and oral formulations in a wide spectrum of *in vivo* and *in vitro* studies in multiple species.

In a guinea pig model for experimental dermatomycosis, ten daily oral doses (10 and 40 mg/kg) of drug were efficacious both in reducing the intensity of infection as well as providing a significant cure.

The administration of single oral dose (5, 20, and 100 mg/kg) to dogs did not affect the cardiovascular parameters such as systolic and diastolic and mean arterial blood pressures, heart rate, QA, P-R, QRS, R-R intervals, and electrocardiograms.

The subcutaneous (1-100 mg/kg) and the topical (0.3-3% solutions) doses of butenafine HCl to guinea pigs and mice did not affect the somatic, and central and autonomic systems, respectively.

Intravenous administration of drug (1, 10, and 100 mg/kg) to dogs caused a slight increase in the respiratory rate at the highest dose level.

An oral dose of 25mg butenafine HCl/kg to rats produced a marked (*p*<0.01) decrease in percent gastric emptying, however, no effect was observed at 1 and 5mg/kg dose levels. In mice, the drug did not affect the intestinal transport when treated with oral doses up to 100mg/kg.

In a single oral dose (5, 25, and 100mg/kg/day) study in a rat model for Irwin test, butenafine did not affect any behavioral or physiological parameters.

In a mice subcutaneous study, at dose levels ranging from 1 to 100mg/kg/day for six weeks, the drug had no affect on the coagulation process. Also no hemolysis or changes in the plasma pharmacokinetics were observed in rabbit blood cells treated *in vitro* with 10⁻⁷M butenafine HCl.

The daily subcutaneous doses of 1-25mg butenafine HCl/kg/day for six weeks produced no change in the levels of various hormones in rats, however, at the highest dose level, a slight hypertrophy of the adrenal glands was observed in females.
The oral LD$_{50}$ in rats, mice, and dogs exceeded 5g/kg. The intravenous and subcutaneous LD$_{50}$ in mice were >140 and >200 mg/kg, respectively; the corresponding values in rats were >100 and >150mg/kg. The primary systemic adverse effects of acute oral doses (up to 5000mg butenafine HCl/kg) in mice, rats, and dogs included decrease in body weight, soft feces, diarrhea, rough coats, and hunched posture. All animals had whitish diarrhea resembling the dosing material. In dogs, in addition to whitish vomitus, changes in some urinary parameters were also observed. Following the intravenous (0-140mg/kg) or subcutaneous (0-200mg/kg) doses, rodents at the highest dose level showed a dose-related decrease in gain in body weights, reduced mobility in the high-dose rats, and erythema or swelling at the site of administration. All adverse effects were reversed during the 14 days observation period. At necropsy, no drug-induced gross lesions were found.

Following seven daily oral doses (up to 1500mg/kg/day) of butenafine HCl to rats, a decreased gain in body weight, increased weights of liver, kidneys, and adrenals, and reduced weights of thymus, heart, and spleen, were observed at 500 and 1500mg/kg dose level. The macroscopic lesions in a few highest-dose rats included distended, impacted stomachs, and small prostate and thymus. In beagle dogs, seven daily oral doses (1-500mg/kg) of drug caused decrease in food consumption, body weights and physical activity.

In a 28-day oral (5-320 mg/kg/day) toxicity study in rats, the significant drug related changes at 80 and 320 mg/kg levels included decreased body weights, and increased weights of liver and kidneys, however, the related histopathologic changes were observed only in the liver. These lesions included hepatocyte hypertrophy, hepatocyte necrosis, and mixed inflammatory infiltrates in 80mg/kg females and in both sexes at 320mg/kg level. The electronmicroscopic examination of liver revealed more pronounced microsteatosis in the males than females of the highest dose group. There was no evidence for peroxisome proliferation. The microscopic lesions in the lungs included histiocytic infiltrates in females of 320mg/kg group. The NOAELs of 80 and 20mg/kg/day were established in male and female rats, respectively.

In a parallel 28-day oral toxicity study (5-1000mg/kg/day) in beagle dogs, blue/pale mucous membranes, vomitus, decreased activity, and salivation observed within two hours of dosing were restricted to the high-dose groups. At the time of dosing, tremors and convulsions were also observed in two males of this group. The drug-related lesions also restricted to the males in the 1000mg/kg group included the bone marrow hypocellularity, albuminous degeneration and hepatocyte vacuolation in the liver, and lymphoid depletion in the lymph nodes and thymus. The electronmicroscopic
examination revealed moderate to marked microsteatosis in males and females of 1000mg group. A slight increase in the amount of smooth endoplasmic reticulum was observed at 160 and 1000mg/kg/day levels. There was no evidence for peroxisome proliferation. The NOAEL for both the sexes was considered to be 160mg/kg/day.

In a 28-day topical (15, 30, 60, and 180mg butenafine HCl/kg/day) study in mice, epidermal hyperplasia (4/5) was observed only in the females of 60mg/kg/day group. In the highest dose males, an increase (11%, p<0.05) in relative (to body) liver weight was observed.

Following subcutaneous injections of butenafine HCl to rats at doses up to 25mg/kg/day for three months, and at 5mg/kg for six months, the local reactions included thickening of the skin and nodule formation at the site of drug administration. These changes were associated with microscopic lesions of intradermal hemorrhage and abscess. The severity of these lesions was markedly reduced during the one-month recovery period. The clinical signs for systemic toxicity restricted to the high-dose groups included decreased body weights and food consumption, changes in a few clinical pathology parameters, and increased weights of liver and spleen. According to the study author, such nonspecific effects are frequently associated with exposure to allylamines.

In a 12-month dermal study in 9 months old beagle dogs (0, 25, 50, and 100mg/kg/day), drug-related lesions were restricted to the application sites in all groups including controls. These lesions included slight keratosis (hyperkeratosis and parakeratosis) and acanthosis. In addition, the mid- and high-dose animals of both the sexes indicated slight small round cell infiltration and swelling of sebaceous glands. No systemic effects were observed. The NOEL was considered to be 25mg/kg/day.

The subcutaneous doses of 0.25, 2.5, or 25.0mg/kg butenafine HCl administered to rats prior to mating, during the mating period, and through seventh day of pregnancy, did not produce any change in fertility. The same subcutaneous doses administered during the organogenesis period caused no maternal toxicity, or changes in fetal development. Similarly, no changes in sexual maturity, reproductive function, or postnatal differentiation were observed at the same subcutaneous doses administered during the perinatal and postnatal periods. In an oral (960, 2,400, and 4,800mg butenafine HCl/m²) teratogenicity study in rabbits, no treatment-related external, visceral, or skeletal malformations or variations were observed.

In two in vitro tests (Ames reverse mutation, and chromosomal aberration assays in Chinese hamster lymphocytes) and in vivo micronucleus assay in rats indicated that butenafine HCl was nonmutagenic and nonclastogenic.
The butenafine HCl Optimized Cream 1% tested as a mild dermal irritant in a rabbit primary irritation test. However, the same formulation produced no ocular irritation in rabbits.

Butenafine tested negative in a photosensitization test in rats and guinea pigs. None of the butenafine formulations at 1% strength were phototoxic to guinea pigs.

One hour after the administration of a radioactive oral (0.2mg/kg) or subcutaneous dose (1mg/kg) of butenafine HCl, approximately 1.5-3% of the administered radioactivity appeared in the plasma. It was determined that >90% of this radioactivity was bound to the serum proteins. A biphasic elimination of butenafine with a terminal half-life ranging from 15 to 36 hours was recorded. It was suggested that the long half-life be related to a significant distribution of drug, and its slow elimination from the adipose tissue.

In an in vitro percutaneous absorption assay using dermatomed human skin mounted on diffusion cells, $^{14}$C-butenafine HCl solution 1% delivered double the radioactivity (~6% of the applied dose) to the receptor fluid that achieved from the $^{14}$C-butenafine HCl nail gel 8% (~3%).

Following the administration of 7 daily oral doses to rats (1-1500mg/kg/day) and dogs (1-1200mg/kg/day), only after the last dose, the parent drug and its metabolites in the plasma were detected at all dose levels. In rats, the largest amount of ~6 ug/mL was detected at 8 hours post-dose in females of the highest dose group. The highest amount of ~8 ug/mL was found in male dogs of 1200mg/kg group at one hour post-dose after dose 7. However, no dose-related trend was observed in either of the species.

After 28 daily oral doses of butenafine HCl (5-320mg/kg/day), no dose, time, or sex-related trends were observed in rats. The highest amount of ~6ug/mL of butenafine was detected at 8 hours post-dose after the first dose in one male of the highest dose group. The plasma concentration of drug and its metabolites in the highest dose group ranged from 1-6ug/mL after the first dose; the values after the last dose ranged from 1 to 5ug/mL. The corresponding values at the next lower dose level (80mg/kg) ranged from 1-2ug/mL after the first as well as after the last dose.

In a 28-day dermal study in mice with butenafine nail gel 8% (15, 30, 60, and 180mgbutenafine/kg/day), the plasma level of the major metabolite N-4-(2 hydroxy-1,1-dimethyl)-benzyl-N-methyl-1-naphthalenemethylamine (M2) represented approximately 1/5 to 1/3 of the parent drug.

After a single oral radioactive dose to rats, approximately 3% of the administered dose (0.2mg/kg) was absorbed, however, less than 0.03% of the parent drug was found in the plasma within 4 hours of dosing, indicating a significant first-pass metabolism. It is suggested that butenafine has some inhibitory effect on the cytochrome P-450 drug
metabolizing enzymes. The parent drug, rapidly metabolized by methylation, dealkylation, and hydroxylation, is not detected in the liver, bile, and urine. The analysis of hydrolyzed samples of bile and urine indicated extensive conjugation of three known metabolites. In the 7 and 28-day oral rat studies, three well characterized metabolites, 1-naphtoic acid, N-4- (2-hydroxy-1,1-dimethyl)-benzyl-N-methyl-1-naphthalenemethylamine, and naphthoylglycine, and two unknown metabolites (UNK1 and UNK2) of butenafine were found. The level of the major metabolite (1-naphtoic acid) in the plasma ranged between 1 to 100% of the administered parent drug.

Butenafine and its metabolites were primarily found in the gut, liver, pancreas, and adrenals of rats. About 60% of the administered drug was found in the bile, almost entirely in the form of conjugated metabolites. A low level of drug is transferred through the placenta, however, the tissue distribution of drug in the fetus was similar to the maternal distribution.

Butenafine is extensively excreted in the milk, reaching a peak level six-fold greater than the plasma level within three hours of a single subcutaneous dose.

Labeling: The Division of Over-the Counter Drug Products will draft the label.

Regulatory recommendation: None

Regulatory conclusion: I have no objection to Rx-to-OTC switch for butenafine HCl Cream 1%.

/Kumar D. Mainigi, Ph.D., M.P.H., D.A.B.T.

CC: Original NDA file
HFD-540
HFD-82
HFD-560
Pharm/Mainigi
MO/Porres
Chem/Pappas
CSO/Cross

Concurrence:
A. Jacobs/TL 540
J. Wilkin/Dir-540